Abeona’s gene therapy ABO-102 shows durable treatment effect in Sanfilippo study – Seeking Alpha
Pharmaceutical Processing |
Abeona's gene therapy ABO-102 shows durable treatment effect in Sanfilippo study
Seeking Alpha One-year data from Cohort 1 in Abeona Therapeutics' (ABEO -1.9%) Phase 1/2 clinical trial assessing a single IV injection of gene therapy ABO-102 in patients with Sanfilippo syndrome Type A (MPS IIIA) showed a significant and durable treatment effect. Commercial Gene Therapy Manufacturing Facility Slated For … Abeona Announces Top-Line One Year Data from ABO-102 MPS IIIA Trial at ARM's Cell & Gene Meeting on the Mesa Contrasting Abeona Therapeutics (ABEO) & Arena Pharmaceuticals (ARNA) |
